[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-grade-serous-ovarian-carcinoma-hgsoc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-grade-serous-ovarian-carcinoma-hgsoc":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,80,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100551922","ov-precision-study-examining-the-benefit-of-a-tumor--and-patient-specific-cancer-therapy-100551922",false,"NCT06466382","OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy","OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.","OVPrecision","Inclusion Criteria:\n\n* Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV\n* No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis\n* Envisaged surgical candidate for interval debulking after 2 cycles of treatment\n* Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures\n* ECOG 0-2\n* Written informed consent according to national legal and regulatory requirements prior to any project specific procedures\n\nExclusion Criteria:\n\n* Elevated liver enzymes (double of normal range: ASAT \\> 68 U\u002Fl; ALAT \\> 82 U\u002Fl; GGT \\> 80 U\u002Fl)\n* Elevated creatinine (double of normal range: \\>120 mmol\u002Fl))\n* ECOG ≥3\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has an impact on the prognosis of the patient\n* Inability to swallow tablets\n* Concurrent participation in another clinical trial on the same indication\n* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance","FEMALE","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.",[27,28,29,30],"Ovarian Neoplasm Epithelial","Fallopian Tube Neoplasms","Ovarian Endometrioid Carcinoma","High-grade Serous Ovarian Carcinoma (HGSOC)",[32,33,34,35,36,37,38,39],"Primary ovarian cancer (OC)","Treatment naiive","Multi-modal tumor profiling","Treatment recommendation process","Multi-disciplinary tumor board","Patient benefit","Quality of Life (QoL)","Patient-personalized therapy","RECRUITING","2026-05-04",{"date":43,"type":44},"2026-05-05","ACTUAL",{"date":46,"type":44},"2025-03-31",{"date":48,"type":21},"2028-09",{"name":50,"class":51},"Swiss GO Trial Group","NETWORK",7,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100552724","phase-1-a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-escalating-doses-of-bms-986463-in-participants-with-select-advanced-malignant-tumors-100552724","NCT06476808","A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","A Phase 1\u002F1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors","Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.\n* Participants must have an unresectable\u002Fmetastatic carcinoma.\n\nExclusion Criteria\n\n* Participants must not have Leptomeningeal metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL",{"count":62,"type":21},240,[64],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.",[30,67,68],"Uterine Serous Carcinoma (USC)","Non-small Cell Lung Cancer (NSCLC)","2026-04-13",{"date":71,"type":44},"2026-04-15",{"date":73,"type":44},"2024-09-06",{"date":75,"type":21},"2028-12-19",{"name":77,"class":78},"Bristol-Myers Squibb","INDUSTRY",17,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100628405","a-translational-study-to-explore-and-overcome-metabolic-driven-resistance-mechanisms-to-standard-chemotherapy-in-high-grade-ovarian-cancer-100628405","NCT07461207","A Translational Study to Explore and Overcome Metabolic-driven Resistance Mechanisms to Standard Chemotherapy in High-grade Ovarian Cancer","TEX-MECS","Inclusion Criteria:\n\n* Age\\>= 25 years\n* Obtained informed consent\n* Histological and\u002For surgical diagnosis of high-grade serous ovarian carcinoma\n* Patients who have not undergone surgical treatment\n* Availability of primary\u002Fmetastatic tumor tissue for sampling\n\nExclusion Criteria:\n\n* Patients with comorbidities\n* Patients with other malignancies",{"count":88,"type":21},120,"OBSERVATIONAL","This translational study, titled \"A translational study to explore and overcome metabolic-driven resistance mechanisms to standard chemotherapy in high-grade ovarian cancer,\" is designed as a prospective, monocentric, observational cohort study utilizing biological material. The primary objective of this research is to evaluate the functional capacity of the U-Cup bioreactor to predict the clinical response to standard chemotherapy in patient-derived high-grade ovarian cancer tissues maintained in perfusion culture. As a secondary objective, the study seeks to develop a high-throughput platform for the personalized assessment of therapeutic responses. This platform will specifically focus on ovarian cancer cases that demonstrate resistance to standard chemotherapy, exploring their sensitivity to alternative metabolic-driven therapies.\n\nThe study population consists of women diagnosed with high-grade serous ovarian carcinoma who have not previously undergone chemotherapy. These patients are candidates for surgical intervention at the UOC Ginecologia Oncologica De Iaco - IRCCS AOUBO. Eligibility for the study is strictly defined by specific inclusion and exclusion criteria to ensure a homogeneous and clinically relevant cohort. Inclusion requires patients to be 25 years of age or older, provide informed consent, and have a confirmed histological or surgical diagnosis of high-grade serous ovarian cancer. Furthermore, eligible participants must not have undergone prior surgical treatment for this malignancy and must have sufficient primary or metastatic tumor tissue available for sampling. Conversely, the study excludes patients presenting with significant comorbidities or those affected by other concurrent malignancies. Over a planned duration of 36 months, the study aims to enroll a total of 120 patients.\n\nFor all parameters measured, including drug response tests related to the secondary objective, data will first undergo the Shapiro-Wilk test to assess the normality of distribution. Continuous variables following a normal distribution will be analyzed using the Student's T-test, while non-normally distributed variables will be evaluated using the Mann-Whitney U test. Categorical variables will be assessed using the Chi-square test or Fisher's exact test, depending on the distribution characteristics. Specifically, for the primary objective, clinical data will be utilized to group patients based on their Chemotherapy Response Score (CRS), comparing those with a high response (CRS3) against those with partial or no response (CRS1\u002F2). The analysis will focus on identifying significant differences in proliferation variation (measured via Ki67-positive nuclei), apoptosis (cleaved Caspase-3 positivity), and necrosis (as evaluated by pathological assessment of HE staining) between SCT-treated and untreated samples. This comparative analysis aims to determine if one or more of these biological parameters can reliably predict a patient's clinical response to standard treatment. To further refine these findings, Area Under the ROC Curve (AUROC) analysis and logistic regression will be employed to define optimal threshold values. These thresholds will be used to discriminate between CRS3 and CRS1\u002F2 patients with high sensitivity and specificity, ultimately validating the bioreactor platform as a predictive tool for personalized oncology.",[30],"NOT_YET_RECRUITING","2026-03-10",{"date":95,"type":44},"2026-03-12",{"date":97,"type":21},"2026-03",{"date":99,"type":21},"2029-03",{"name":101,"class":102},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100371101","phase-3-maintenance-therapy-with-aromatase-inhibitor-in-epithelial-ovarian-cancer-matao-100371101","NCT04111978","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54\u002FSwiss-GO-2\u002FMATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).","MATAO","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Willing and able to attend the visits and to understand all study-related procedures.\n* Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian\u002Ffallopian tube\u002Fperitoneal cancer\n* (Interval-) debulking performed ECOG-Performance Status 0-2\n* Signed informed consents (ICF-1; ICF-2)\n* Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available\n* Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)\n* At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)\n* Negative serum pregnancy test in women of childbearing potential who will get\u002Fhave gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.\n\nExclusion Criteria:\n\n* Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol\n* Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has impact on the prognosis of the patient\n* \\\u003C 4 cycles of chemotherapy in total\n* Contraindications to endocrine therapy\n* Inability or unwillingness to swallow tablets\n* Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption",{"count":113,"type":21},540,[115],"PHASE3","The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.\n\nThe study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).",[27,28,118,30,119,29],"Peritoneal Neoplasms","Low-grade Serous Ovarian Carcinoma (LGSOC)",[121,122,123,124],"maintenance therapy","aromatase inhibitor","primary ovarian cancer","estrogen-receptor","2025-09-23",{"date":127,"type":44},"2025-09-29",{"date":129,"type":44},"2020-11-05",{"date":131,"type":21},"2032-07-01",{"name":50,"class":51},53]